Manufacturing of a Prothrombin Complex Concentrate Aiming at Low Thrombogenicity
- 1 December 2000
- journal article
- Published by Elsevier in Thrombosis Research
- Vol. 100 (5) , 433-441
- https://doi.org/10.1016/s0049-3848(00)00339-x
Abstract
No abstract availableThis publication has 18 references indexed in Scilit:
- Thrombogenicity of Prothrombin Complex ConcentratesThrombosis Research, 1999
- Thromboembolic Complications Associated with the Use of Prothrombin Complex and Factor IX ConcentratesThrombosis and Haemostasis, 1998
- Factor VII and Activated‐ Factor‐VII Content of Prothrombin Complex Concentrates1Vox Sanguinis, 1997
- Application of compact porous tubes for preparative isolation of clotting factor VIII from human plasmaJournal of Chromatography A, 1997
- Management of Acquired Coagulation Disorders in Emergency and Intensive-Care MedicineSeminars in Thrombosis and Hemostasis, 1996
- Considerations for current and future management of haemophilia and its complicationsHaemophilia, 1995
- The coagulant-active phospholipid content is a major determinant of in vivo thrombogenicity of prothrombin complex (Factor IX) concentrates in rabbitsBlood, 1982
- Activated factor VII: presence in factor IX concentrates and persistence in the circulation after infusionBlood, 1979
- In vitro and in vivo correlation of clotting protease activity: Effect of heparinProceedings of the National Academy of Sciences, 1977
- STUDIES IN INTRAVASCULAR COAGULATION. III. THE PATHOGENESIS OF SERUM-INDUCED VENOUS THROMBOSIS 12Journal of Clinical Investigation, 1955